ATE210656T1 - Heterocyclische ether-derivate zur verstärkung der cognitiven funktionen - Google Patents

Heterocyclische ether-derivate zur verstärkung der cognitiven funktionen

Info

Publication number
ATE210656T1
ATE210656T1 AT93923826T AT93923826T ATE210656T1 AT E210656 T1 ATE210656 T1 AT E210656T1 AT 93923826 T AT93923826 T AT 93923826T AT 93923826 T AT93923826 T AT 93923826T AT E210656 T1 ATE210656 T1 AT E210656T1
Authority
AT
Austria
Prior art keywords
heterocyclic ether
ether derivatives
cognitive functions
enhance cognitive
cholinergic
Prior art date
Application number
AT93923826T
Other languages
English (en)
Inventor
Melwyn A Abreo
David E Gunn
Nan-Horng Lin
Richard L Elliott
David S Garvey
Suzanne A Lebold
James T Wasicak
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of ATE210656T1 publication Critical patent/ATE210656T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT93923826T 1992-10-09 1993-10-08 Heterocyclische ether-derivate zur verstärkung der cognitiven funktionen ATE210656T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95900592A 1992-10-09 1992-10-09
PCT/US1993/009662 WO1994008992A1 (en) 1992-10-09 1993-10-08 Heterocyclic ether compounds that enhance cognitive function

Publications (1)

Publication Number Publication Date
ATE210656T1 true ATE210656T1 (de) 2001-12-15

Family

ID=25501548

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93923826T ATE210656T1 (de) 1992-10-09 1993-10-08 Heterocyclische ether-derivate zur verstärkung der cognitiven funktionen

Country Status (12)

Country Link
EP (1) EP0663912B1 (de)
JP (1) JP3098035B2 (de)
KR (1) KR100311546B1 (de)
AT (1) ATE210656T1 (de)
AU (1) AU687017B2 (de)
CA (1) CA2136075C (de)
DE (1) DE69331329T2 (de)
DK (1) DK0663912T3 (de)
ES (1) ES2169727T3 (de)
IL (1) IL107184A (de)
PT (1) PT663912E (de)
WO (1) WO1994008992A1 (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948793A (en) * 1992-10-09 1999-09-07 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling neurotransmitter release
US5852041A (en) * 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
US5605908A (en) * 1994-10-24 1997-02-25 Eli Lilly And Company Heterocyclic compounds and their use
US5998404A (en) 1994-10-24 1999-12-07 Eli Lilly And Company Heterocyclic compounds and their use
US5585388A (en) * 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
IL118279A (en) * 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
JP2000500452A (ja) * 1995-11-13 2000-01-18 イーライ・リリー・アンド・カンパニー 不安の処置法
US5794887A (en) 1995-11-17 1998-08-18 Komerath; Narayanan M. Stagnation point vortex controller
US6979695B2 (en) 1996-04-23 2005-12-27 Targacept, Inc. Compounds capable of activating cholinergic receptors
US5629325A (en) * 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US6437138B1 (en) 1996-06-06 2002-08-20 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
IL130083A0 (en) * 1996-12-10 2000-02-29 Abbott Lab 3-Pyridyl enantiomers and their use as analgesics
US6133253A (en) * 1996-12-10 2000-10-17 Abbott Laboratories 3-Pyridyl enantiomers and their use as analgesics
EP0978280A1 (de) * 1997-04-26 2000-02-09 Sumitomo Pharmaceuticals Company, Limited 2-azabicyclo verbindungen
US6624173B1 (en) 1997-06-30 2003-09-23 Targacept, Inc. Pharmaceutical compositions for treating and/or preventing CNS disorders
US7214686B2 (en) 1997-06-30 2007-05-08 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
US6525065B1 (en) 1997-06-30 2003-02-25 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
EP1034174B1 (de) 1997-11-05 2003-08-13 Neurosearch A/S Azaring-ether-derivate und ihre verwendung als nicotinic-ach-rezeptormodulatoren
ES2221234T3 (es) * 1997-12-19 2004-12-16 Abbott Laboratories Compuestos de eter y tioeter heterociclicos utilizados en la regulacion de la transmision sinaptica quimica.
CA2317572A1 (en) 1998-04-02 1999-10-14 Jared Miller Wagner Pharmaceutical compositions and methods for use
WO1999051602A1 (en) * 1998-04-02 1999-10-14 R.J. Reynolds Tobacco Company Azatricyclo[3.3.1.1] decane derivatives and pharmaceutical compositions containing them
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
US6432975B1 (en) * 1998-12-11 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
US20010031771A1 (en) 1999-05-24 2001-10-18 Gary Maurice Dull Pharmaceutical compositions and methods for use
US6544976B1 (en) 1999-07-09 2003-04-08 Ortho-Mcneil Pharmaceutical, Inc. Neurotrophic 2-azetidinecarboxylic acid derivatives, and related compositions and methods
EP1212319A2 (de) * 1999-09-14 2002-06-12 Abbott Laboratories 3-pyrrolidinyloxy-3' -pyridyl ether verbindungen verwendbar zur steuerung von chemischer synaptischer übertragung
US6890935B2 (en) 1999-11-01 2005-05-10 Targacept, Inc. Pharmaceutical compositions and methods for use
US6812314B2 (en) 2001-10-17 2004-11-02 University Of Florida Thermally responsive polymer materials and uses thereof
CA2470567A1 (en) 2001-12-14 2003-06-26 Targacept, Inc. Methods and compositions for treatment of central nervous system disorders
EP1519939B9 (de) 2002-07-05 2011-04-06 Targacept, Inc. N-aryl diazaspirozyklische verbindungen, deren verwendung und das verfahren zu ihren herstellung
AU2003254016A1 (en) 2002-07-19 2004-02-09 Catholic Healthcare West Methods and compositions relating to chimeric nicotinic receptor subunits
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
US7098331B2 (en) 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof
WO2005037832A2 (en) 2003-10-15 2005-04-28 Targacept, Inc. Azabicycyclic compounds for relieving pain and treating central nervous system disorders
PE20060437A1 (es) 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
AU2005284908B2 (en) 2004-09-13 2011-12-08 Morningside Venture Investments Limited Biosynchronous transdermal drug delivery
AU2005287037A1 (en) 2004-09-20 2006-03-30 Targacept, Inc. Azaspiroalkene and azaspiroalkane compounds with nicotinic cholinergic receptor activity
UA88792C2 (ru) 2004-11-10 2009-11-25 Таргасепт, Інк. Гидроксибензоатные соли метаникотиновых соединений
US7459469B2 (en) 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
ATE482959T1 (de) 2005-08-22 2010-10-15 Targacept Inc Heteroarylsubstituierte diazatricycloalkane, verfahren zu deren herstellung und deren anwendung
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
TWI389889B (zh) 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
JP2009536665A (ja) 2006-05-09 2009-10-15 アストラゼネカ・アクチエボラーグ （２ｓ）−（４ｅ）−ｎ−メチル−５−［３−（５−イソプロポキシピリジン）イル］−４−ペンテン−２−アミンの新規な塩形態
TWI404532B (zh) 2006-11-02 2013-08-11 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
KR20090095608A (ko) * 2006-11-29 2009-09-09 바스프 에스이 해충 방제용 피리딘 화합물
WO2008091592A1 (en) 2007-01-22 2008-07-31 Targacept, Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
TW200845977A (en) 2007-03-30 2008-12-01 Targacept Inc Sub-type selective azabicycloalkane derivatives
ES2521494T3 (es) 2007-04-02 2014-11-12 Parkinson's Institute Métodos y composiciones para la reducción de los efectos secundarios de tratamientos terapéuticos
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
CN101883771A (zh) 2007-10-01 2010-11-10 科门蒂斯公司 作为α7-烟碱乙酰胆碱受体配体用于治疗阿尔茨海默氏病的奎宁环-4-基甲基1H-吲哚-3-甲酸酯衍生物
MX2011003306A (es) * 2008-10-14 2011-09-01 Psychogenics Inc Ligandos nicotinicos de receptor de acetilcolina y los usos de los mismos.
TW201024283A (en) 2008-12-01 2010-07-01 Targacept Inc Synthesis and novel salt forms of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
CA2742366C (en) 2008-12-01 2020-09-22 Targacept, Inc. Synthesis and salt forms of (r)-5-((e)-2-(pyrrolidin-3-ylvinyl)pyrimidine
WO2010080757A2 (en) 2009-01-07 2010-07-15 Astrazeneca Ab Combinations with an alpha-4beta-2 nicotinic agonist
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
PE20121556A1 (es) 2009-12-07 2012-12-05 Targacept Inc 3,6-diazabiciclo[3.1.1]heptanos como ligandos de receptores nicotinicos neuronales de acetilcolina
BR112012029326A2 (pt) 2010-05-20 2017-08-08 Astrazeneca Ab processo para a preparação de animais olefínicas substituídas por arila
KR101856046B1 (ko) 2010-05-27 2018-06-25 카탈리스트 바이오사이언시즈, 인코포레이티드 니코틴 수용체 비-경쟁적 길항제
WO2012125518A1 (en) 2011-03-14 2012-09-20 Targacept, Inc. Salt forms of 3 - cyclopropylcarbonyl - 3, 6 - diazabicyclo [3.1.1] heptane
WO2012129262A1 (en) 2011-03-23 2012-09-27 Targacept, Inc. Treatment of attention deficit/hyperactivity disease
TW201311698A (zh) 2011-08-22 2013-03-16 Targacept Inc 作為神經元菸鹼乙醯膽鹼受體配位體之１，４－二氮雜雙環［３．２．２］壬烷
US9303017B2 (en) 2011-11-11 2016-04-05 Georgetown University 2,5-disubstituted-pyridyl nicotinic ligands, and methods of use thereof
JP2017524736A (ja) 2014-07-11 2017-08-31 アルファーマゲン，エルエルシー アルファ７−ニコチン性アセチルコリン受容体活性を調節するためのキヌクリジン化合物
WO2016123406A1 (en) 2015-01-28 2016-08-04 Chrono Therapeutics Inc. Drug delivery methods and systems
US9724340B2 (en) 2015-07-31 2017-08-08 Attenua, Inc. Antitussive compositions and methods
CN105418477B (zh) * 2015-12-22 2018-12-21 爱斯特（成都）生物制药股份有限公司 降低雷迪帕韦中间体中非对映异构体杂质含量的方法
CA3049529A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
CA3101966A1 (en) 2018-05-29 2019-12-05 Morningside Venture Investments Limited Drug delivery methods and systems
US12397141B2 (en) 2018-11-16 2025-08-26 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system
KR20230027151A (ko) * 2020-06-24 2023-02-27 필립모리스 프로덕츠 에스.에이. 기생충 방제를 위한 조성물 및 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA848275B (en) * 1983-12-28 1985-08-28 Degussa New piridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring
CA1307790C (en) * 1987-08-04 1992-09-22 Ian Anthony Cliffe Ethers
YU84791A (sh) * 1990-05-19 1994-06-10 Boehringer Ingelheim Kg. Biciklicni 1-aza-cikloalkalni

Also Published As

Publication number Publication date
EP0663912B1 (de) 2001-12-12
DK0663912T3 (da) 2002-04-15
JP3098035B2 (ja) 2000-10-10
IL107184A (en) 1997-08-14
CA2136075A1 (en) 1994-04-28
AU5355794A (en) 1994-05-09
JPH08502481A (ja) 1996-03-19
EP0663912A4 (de) 1995-02-17
IL107184A0 (en) 1994-01-25
CA2136075C (en) 2004-12-14
AU687017B2 (en) 1998-02-19
WO1994008992A1 (en) 1994-04-28
EP0663912A1 (de) 1995-07-26
DE69331329T2 (de) 2002-08-08
KR100311546B1 (ko) 2005-12-06
KR950701920A (ko) 1995-05-17
DE69331329D1 (de) 2002-01-24
ES2169727T3 (es) 2002-07-16
PT663912E (pt) 2002-06-28

Similar Documents

Publication Publication Date Title
ATE210656T1 (de) Heterocyclische ether-derivate zur verstärkung der cognitiven funktionen
FI931888A0 (fi) Kramploesande cykliska fruktopyranossulfiter -och sulfater
SE8101409L (sv) Karbostyrilderivat och forfarande for framstellning derav
PT870768E (pt) Derivados azaindole-etilamina como agentes de ligacao nicotinicos aos receptores de acetilcolina
GB9408185D0 (en) New benzamide derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same
DE69505470D1 (de) Pyrrolocarbazol
IL118367A0 (en) Heteroaroyl derivatives
TW429255B (en) Pyrazine compounds having treatment of central nervous system diseases and disorders
DE69933885D1 (de) Triphenylbutenderivate zur behandlung von neurologischen störungen
DK0623131T3 (da) Alkylderivater af trazodon med CNS-aktivitet
DE3061188D1 (en) 2-sulfonyl-quinoxalines, processes for their preparation and their use as microbicides
PT1049672E (pt) Derivados de azetidinocarboxamida para o tratamento de disturbios do snc
SE8901060D0 (sv) New compounds
DK52383D0 (da) Fremgangsmade til fremstilling af carbacyklinderivater
DK0784973T3 (da) Quinoxalinderivater til behandling af tinnitus
AU2178199A (en) Azetidinecarboxamide derivatives for the treatment of cns disorders
PT1049670E (pt) Derivados de azetidinocarboxamida para o tratamento de perturbacoes do snc
ATE28628T1 (de) Phenylethylaminderivate und ihre zwischenprodukte.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification